stars 1 stars 2 stars 3

GenoFocus is a microbiome therapeutics platform company. We engage in identifying effector molecules that are now well-known as postbiotics in a bid to discover new drug candidates. By enhancing strains to better produce these effector molecules such as but not limited to SOD, Spore, etc., we develop a class of our own biological drugs. Our microbiome therapeutics are designed to restore enteric health in patients where 98% of the microbiome are found by treating dysbiosis in the enteric microbiome. While having collaboration with top-tier university hospitals, research and development centers, government associations, etc., we keep advancing our pipelines of precision microbiome therapeutics. GenoFocus has been engaging in enzyme solutions business for specialty food, biopharmaceuticals, cosmeceuticals, agriculture, etc through the eco-friendly process using our platform technology. Our enzyme products are developed through molecular evolution using smart library generation and microbial display-based high throughput screening. With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.

GenoFocus Inc. Questions

The GenoFocus Inc. annual revenue was $7.5 million in 2026.

Eui-Joong Kim is the CEO of GenoFocus Inc..

4 people are employed at GenoFocus Inc..

GenoFocus Inc. is based in Daejeon, Daejeon.

The NAICS codes for GenoFocus Inc. are [54, 54171, 541713, 5417, 541].

The SIC codes for GenoFocus Inc. are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users